Golimumab reduces disease activity of rheumatoid arthritis for 1 year and strongly inhibits radiographic progression in Japanese patients: Partial but detailed results of the GO-FORTH and GO-MONO studies

Clinical Rheumatology

Volumn 32, Issue 7, 2013, Pages 961-967

  Hayashi, Masatoshi ^a   Kobayakawa, Tomonori ^a   Takanashi, Tetsuo ^b   Yamazaki, Hideshi ^b   Ishikawa, Hisato ^c   Kanamono, Toshihisa ^a  

^a NAGANO RED CROSS HOSPITAL   (Japan)

^b Department of Rheumatology   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Anti TNF inhibitor; Clinical trial; Golimumab; Radiographic progression; Rheumatoid arthritis

Indexed keywords

GOLIMUMAB; METHOTREXATE; PLACEBO;

ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JAPANESE; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JAPAN; MALE; METHOTREXATE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880150428     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2210-x     Document Type: Conference Paper

References (14)

1. Herman S, Kronke G, Schett G (2008) Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med 14(6):245-253
2. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370(9602):1861-1874 (Pubitemid 350180008)
3. Shealy D, Cai A, Staquet K, Baker A, Lacy ER, Johns L et al (2010) Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2(4):428-439
4. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P et al (2009) Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60(8):2272-2283
5. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC et al (2009) Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 68(6):789-796
6. Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC et al (2010) Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 69(6):1129-1135
7. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J et al (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374(9685):210-221
8. Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K et al (2012) Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis 71(6):817-824
9. Koller MD, Aletaha D, Funovits J, Pangan A, Baker D, Smolen JS (2009) Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology (Oxford) 48(12):1575-1580
10. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D et al (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372(9636):375-382
11. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1):26-37 (Pubitemid 43122183)
12. St. Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432-3443 (Pubitemid 39488667)
13. Smolen JS, Van Der Heijde DM, St. Clair EW, Emery P, Bathon JM, Keystone E et al (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54(3):702-710
14. Ling J, Lyn S, Xu Z, Achira M, Bouman-Thio E, Shishido A et al (2010) Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects. J Clin Pharmacol 50(7):792-802